Stem Cell Transplant From Donors After Alpha Beta Cell Depletion in Children and Adults With T-allo10 Cells Addback
Recruiting
Phase 1
Interventional Study
Hematologic Diseases
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 1 Month – 45
- Sex
- Any
- Trial phase
- Phase 1
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 22 (estimated)
- Sponsor
- Porteus, Matthew, MD · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The purpose of this study is to determine the safety of a cell therapy, T-allo10, after αβdepleted-HSCT in the hopes that it will boost the adaptive immune reconstitution of the patient while sparing the risk of developing severe Graft-versus-Host Disease (GvHD).
The primary objective of Phase 1a is to determine the recommended Phase 2 dose (RP2D) administered after infusion of αβdepleted-HSCT in…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria prior to enrollment:
* 1\. Age \> 1 months (with minimum weight of 10 Kg) and \< 45 years.
* 2\. Patients deemed eligible for allogeneic HSCT under the originating study, NCT 04249830
* 3\. Patients with life-threatening hematological malignancies for which HSCT has been recommen…
Contacts
No contact information available.